Summit Partners with AstraZeneca and Daiichi Sankyo on Ivonescimab-Datroway Combo
SMMT sits 39% above its 52-week low of $12.07.
Summary
Summit Therapeutics announced a clinical trial collaboration with AstraZeneca and Daiichi Sankyo to evaluate ivonescimab in combination with Datroway, a TROP2-directed ADC, across multiple solid tumors, starting with a Phase III trial in first-line triple-negative breast cancer. This expands ivonescimab's development into breast cancer and adds a major pharma partnership, following AstraZeneca's recent $2 billion investment in Summit. The collaboration validates ivonescimab's potential as a foundational immunotherapy and could accelerate its path to market in new indications. Each company retains rights to its own drug, with trial costs shared and sponsorship by AstraZeneca or Daiichi Sankyo. The FDA decision on ivonescimab's BLA for EGFR-mutated NSCLC is expected November 14, 2026.
Updates
· Reuters — The collaboration will evaluate Datroway with ivonescimab across multiple tumor types, including lung and breast cancers.
At the time of this announcement, SMMT was trading at $16.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.3B. The 52-week trading range was $12.07 to $29.23. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.